462
Views
16
CrossRef citations to date
0
Altmetric
Original Articles: Research

Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients

, , , , , & show all
Pages 1669-1676 | Received 08 Oct 2015, Accepted 12 Dec 2015, Published online: 12 Jan 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Svetlana A. Smirnikhina, Ekaterina Yu. Chelysheva, Alexander V. Lavrov, Konstantin S. Kochergin-Nikitsky, Ivan V. Mozgovoy, Elmira P. Adilgereeva, Oleg A. Shukhov, Anna N. Petrova, Anastasia V. Bykova, Adhamjon O. Abdullaev, Anna G. Turkina & Sergey I. Kutsev. (2018) Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation. Leukemia & Lymphoma 59:10, pages 2512-2515.
Read now
Sameem Abedin & Leonidas C. Platanias. (2016) Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. Leukemia & Lymphoma 57:7, pages 1503-1504.
Read now

Articles from other publishers (14)

Erfan Zaker, Negar Nouri, Sepehr Sorkhizadeh, Hamidreza Ghasemirad, Amir Hossein Hajijafari & Fateme Zare. (2023) The importance of personalized medicine in chronic myeloid leukemia management: a narrative review. Egyptian Journal of Medical Human Genetics 24:1.
Crossref
Ruth Stuckey, Juan Francisco López Rodríguez & María Teresa Gómez-Casares. (2022) Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission. Current Oncology Reports 24:4, pages 415-426.
Crossref
Huanhuan Sha, Yujie Gan, Renrui Zou, Jianzhong Wu & Jifeng Feng. (2021) Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer. Frontiers in Oncology 11.
Crossref
Yilin Chen, Jing Zou, Fanjun Cheng & Weiming Li. (2021) Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. Frontiers in Oncology 11.
Crossref
David Vogrinc, Katja Goričar & Vita Dolžan. (2021) Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. Frontiers in Aging Neuroscience 13.
Crossref
Lorena Vigón, Alejandro Luna, Miguel Galán, Sara Rodríguez-Mora, Daniel Fuertes, Elena Mateos, Miguel Piris-Villaespesa, Guiomar Bautista, Esther San José, José Rivera-Torres, Juan Luis Steegmann, Fernando de Ory, Mayte Pérez-Olmeda, José Alcamí, Vicente Planelles, María Rosa López-Huertas, Valentín García-Gutiérrez & Mayte Coiras. (2020) Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Journal of Clinical Medicine 10:1, pages 42.
Crossref
Ruth Stuckey, Juan Francisco López-Rodríguez, Santiago Sánchez-Sosa, Adrián Segura-Díaz, Nuria Sánchez-Farías, Cristina Bilbao-Sieyro & María Teresa Gómez-Casares. (2020) Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. World Journal of Clinical Oncology 11:12, pages 996-1007.
Crossref
Svetlana A. Smirnikhina, Ekaterina V. Kondrateva, Elmira P. Adilgereeva, Arina A. Anuchina, Milyausha I. Zaynitdinova, Yana S. Slesarenko, Angelina S. Ershova, Kirill D. Ustinov, Matvei I. Yasinovsky, Elena L. Amelina, Ekaterina S. Voronina, Valentina D. Yakushina, Vyacheslav Yu. Tabakov & Alexander V. Lavrov. (2020) P.F508del editing in cells from cystic fibrosis patients. PLOS ONE 15:11, pages e0242094.
Crossref
Stina Söderlund, Inger Persson, Mette Ilander, Joëlle Guilhot, Henrik Hjorth-Hansen, Perttu Koskenvesa, Johan Richter, Susanne Saussele, Satu Mustjoki & Ulla Olsson-Strömberg. (2020) Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy. Leukemia Research 90, pages 106310.
Crossref
Miguel Tábuas-Pereira, Isabel Santana, Rita Guerreiro & José Brás. (2020) Alzheimer’s Disease Genetics: Review of Novel Loci Associated with Disease. Current Genetic Medicine Reports 8:1, pages 1-16.
Crossref
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker & Jeffrey W. Tyner. (2019) Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications 10:1.
Crossref
Lanlan Zang, Shukkoor Muhammed Kondengaden, Fengyuan Che, Lijuan Wang & Xueyuan Heng. (2018) Potential Epigenetic-Based Therapeutic Targets for Glioma. Frontiers in Molecular Neuroscience 11.
Crossref
Alexander V. Lavrov, Oksana A. Ustaeva, Elmira P. Adilgereeva, Svetlana A. Smirnikhina, Ekaterina Y. Chelysheva, Oleg A. Shukhov, Yuriy V. Shatokhin, Sergey V. Mordanov, Anna G. Turkina & Sergey I. Kutsev. (2017) Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia. PLOS ONE 12:9, pages e0182901.
Crossref
A. G. Turkina, E. Yu. Chelysheva, V. A. Shuvaev, G. A. Gusarova, A. V. Bykova, O. A. Shukhov, A. N. Petrova, M. V. Vakhrusheva, S. R. Goryacheva, L. Yu. Kolosova, P. S. Krasikova, M. S. Fominykh, I. S. Martynkevich, A. O. Abdullaev, A. B. Sudarikov & V. G. Savchenko. (2017) Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy. Terapevticheskii arkhiv 89:12, pages 86.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.